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1. Introduction 
MicroRNAs (miRNAs) are endogenously expressed small non-coding RNAs that act as 
post-transcriptional regulators of gene expression. Dysregulation of these molecules has 
been observed in many types of cancers. Altered expression levels of several miRNAs were 
identified also in gliomas. It was many times showed that miRNAs are involved in core 
signaling pathways, which play roles in crucial cellular processes, such as proliferation, 
apoptosis, cell cycle regulation, invasion, angiogenesis and stem cell behaviour. Therefore, 
miRNAs have a great potential for oncodiagnostic as well as could be promising therapeutic 
targets in gliomas. 
2. MicroRNA: Function and biogenesis 
MicroRNAs (miRNAs) comprise a numerous class of endogenous small non-coding RNAs, 
18 – 25 nucleotides in length, which function as post-transcriptional regulators of gene 
expression. The regulation proceeds through binding of miRNAs to their mRNA targets 
(Bartel, 2004). Currently, the miRBase annotates over 800 verified miRNA sequences in the 
human genome and the number is still expanding (Griffiths-Jones et al., 2008). 
Bioinformatics and cloning studies have estimated that miRNAs may regulated more than 
50% of all human genes and each miRNA can control hundreds of gene targets. This is 
possible among others due to the fact that the binding of miRNA to the mRNA doesn’t 
require perfect complementarity. MiRNAs are highly conserved in sequence between 
distantly related organisms, indicating their participation in essential biological processes. It 
is well known today that miRNAs are involved in many signaling pathways playing crucial 
roles in such cellular processes as differentiation, proliferation, and apoptosis that affect 
biological processes including development and cancerogenesis (Alvarez-Garcia & Miska, 
2005; Carthew & Sontheimer, 2009; Croce, 2009; Hatfield & Ruohola-Baker, 2008; Winter & 
Diederichs, 2011; Lakomy, 2011). A large fraction of miRNAs exhibits strict developmental 
stage-specific and tissue-specific expression patterns. Moreover, the levels of many miRNAs 
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are altered in various disseses including many types of cancers (Krol et al., 2010; Siomi & 
Siomi, 2010; Winter et al., 2009). 
 
Fig. 1. Linear “canonical” pathway of miRNA processing 
Most miRNA genes have own promoters and are transcribed as autonomous transcription 
units (Carthew & Sontheimer, 2009). Primary transcripts (pri-miRNAs) are generated by 
RNA polymerase II. These are processed to short 70-nucleotide stem-loop structures known 
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as pre-miRNAs by the ribonuclease called Drosha and the double-stranded-RNA-binding 
protein known as Pasha. The pre-miRNAs are transported to the cytoplasm where they are 
processed to mature miRNA duplexes by their interaction with the endonuclease enzyme 
Dicer in complex with dsRNA binding protein TRBP (Siomi & Siomi, 2010). One strand of 
the mature miRNA duplex ultimately gets integrated into the miRNA-induced silencing 
complex (miRISC), whereas the second strand is released and degraded. The resulting 
complex of mature miRNA and miRISC exerts regulatory effect by binding to its target site 
in the 3’ untranslated region (3’UTR) of mRNA that controls many aspects of mRNA 
metabolism, such as transport, localization, efficiency of translation and stability (Chiang et 
al., 2010; Krol et al., 2010) (summarized in Fig. 1). 
3. MicroRNAs as potential biomarkers for diagnostic, prediction of therapy 
response, and prognosis of patients 
As described above, the expression levels of many miRNAs are altered in various types of 
cancers. Thus, specific tissue miRNA signature could be an useful tool for diagnostic 
oncology. Among all gliomas, miRNAs are the most studied in glioblastomas that is 
associated with the very poor prognosis. Global analysis of miRNA expression profiles of 
glioblastoma tissues allowed to identify a group of miRNAs with significantly altered 
expression levels compared to non-malignant brain tissues (Sana et al., 2011). Two 
independent research groups described significant up-regulation of miR-21 in glioblastomas 
what fully corresponds to the expression levels of miR-21 observed in other cancers (Chan et 
al., 2005; Esquela-Kerscher & Slack, 2006; Zhang & Farwell, 2008). Furthermore, miR-125b 
was over-expressed, and miR-128a and miRNA-181 family were significantly down-
regulated in both studies. On the other hand, miR-221 generates conflict between these 
studies. Ciafré described this miRNA as up-regulated in glioblastoma, whereas, Slaby 
showed lower level in comparison to the adult brain tissue (Ciafre et al., 2005; Slaby et al., 
2010). The last-named autor speculated this discrepancy and concluded that it is likely that 
the brain tissues used as control samples in their study, though excised from the margin of 
resection materials, contained traces of micro-capillaries from around the arteriovenous 
malformation. This could be responsible for the relatively low levels of miR-221 and miR-
222 in glioblastomas despite their absolute levels because it is generally known that 
endothelial cells are characterized by highest expression levels of these miRNAs (Slaby et 
al., 2010) (Tab. 1). Furthermore, Ciafré performed miRNA expression analysis of several 
glioblastoma cell lines and has come to the conclusion that miRNAs underexpressed in 
glioblastoma cell lines generally confirmed primary tumour data, whereas only miR-21 and 
miR-221 that were overexpressed in tumours were deregulated also in the cell lines (Ciafre 
et al., 2005). Taken together, only miR-21 and miR-181 family were significantly and 
consistently altered in all three studies. 
The clinical significance of miRNA expression profiles in malignant gliomas is not yet much 
explored. Nevertheless, Guan published a set of 16 candidate miRNAs associated with the 
malignant progresiion from anaplastic astrocytomas to glioblastomas. Among these 
miRNAs, the members of miR-196 family, indicated the highest level of significance. MiR-
196 expression levels significantly correlated with poor survival by Kaplan-Meier method  
(p = 0.0073) and, moreover, multivariate analysis showed that its expression levels were an 
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independent predictor of overall survival in glioblastoma patients (p = 0.021; HR 2.81) 
(Guan et al., 2010). Another research group investigated the miRNA expression profiles in 
four patients with primary WHO grade II gliomas that spontaneously progressed to WHO 
grade IV secondary glioblastomas. They identified 12 miRNAs (miR-9, miR-15a, miR-16, 
miR-17, miR-19a, miR-20a, miR-21, miR-25, miR-28, miR-130b, miR-140, and miR-210) 
showing increased expression, and two miRNAs (miR-184 and miR-328) with reduced 
expression upon progression (Malzkorn et al., 2010). Validation experiments on an 
independent series of primary low-grade and secondary high-grade astrocytomas 
confirmed miR-17 and miR-184 as interesting candidates contributing to glioma 
progression. Taken together, only miR-184 was significantly altered in all three studies. 
However, miR-21, which was identified in two independent studies but not confirmed by 
validation study, could also probably play an important role in progression of glioma 
tumors with respect to its oncogene function described in many other cancers. 
Treatment of malignant gliomas remains one of the greatest challenges facing oncologists 
today through a frequent resistance to both chemo- and radiotherapeutics and short 
survival (Ziegler et al., 2008). Important question for management of glioblastoma patients 
is the possibility of predicting therapeutic outcome. MiRNA expression could have a great 
potential in prediction of therapeutic outcome after treatment by temozolomide (TMZ) that 
is an oral alkylating agent frequently used for the treatment of glioblastoma. Slaby showed 
that expression levels of miR-181b and miR-181c in glioblastoma tissued was successfully 
associated with response to concomitant chemoradiotherapy with temozolomide 
(RT/TMZ). MiR-181b and miR-181c were significantly down-regulated in patients who 
responded to RT/TMZ (p = 0.016; p = 0.047, respectively) in comparison to patients with 
progredient disease (Slaby et al., 2010). In other study, Ujifuku described miR-195, miR-455-
3p, and miR-10a* as the three most up-regulated miRNAs in the TMZ-resistant cell lines. 
Moreover, knockdown of miRNA-195 in the TMZ-resistant cell line led to overcome of TMZ 
resistance and increase the cell killing effect of TMZ (Ujifuku et al., 2010). 
4. MicroRNAs involved in drug resistance 
It was many time showed that miRNAs play important role in drug resistance many 
cancers, including glioblastoma. Shi described that overexpression of miR-21 in 
glioblastoma cells could significantly reduce TMZ-induced apoptosis by decreasing 
Bax/Bcl-2 ratio and caspase-3 activity (Shi et al., 2010). The miR-21 inhibitor also enhances 
the chemosensitivity of human glioblastoma cells to paclitaxel via inhibition of STAT3 
expression and phosphorylation. Moreover, the same treatment by miR-21 antisense 
oligonucleotides led to enhanced cytotoxicities of vepesid because miR-21 likely contributes 
to resistance through depression of LRRFIP1 expression, leading to the reduction of 
cytotoxicity of chemotherapeutic drugs through activation of the NF-κB pathway (Li et al., 
2009b; Papagiannakopoulos et al., 2008; Ren et al., 2010). Li observed that miR-328 is in 
glioblastoma poorly expressed and contributes to tumour chemoresistance through 
multidrug resistance protein ABCG2 (Li et al., 2010). Finally, it was reported the possible 
impact on the therapeutic effect by transfection of miR-451 in combination with imatinib 
mesylate treatment. Up-regulation of miR-451 led to differentiation of glioblastoma stem 
cells (Gal et al., 2008). 
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 Ciafre et al., 2005 Slaby et al., 2010 










miR-9-2 1.88 - 10.16   
miR-10b 1.97 - 13.6   
miR-21 1.81 - 9.3 miR-21 8.35 (<0.001) 
miR-25 1.99 - 3.6   
miR-123 1.9 - 2.45   
miR-125b-1 2.19 - 2.73 miR-125b 1.45 (0.502) 
miR-125b-2 1.95 - 2.88   
miR-130a 2.11 - 5.3   











miR-128a 0.34 - 0.56 miR-128a 0.03 (<0.001) 
miR-181a 0.082 - 0.56 miR-181a 0.4 (0.073) 
miR-181b 0.098 - 0.56 miR-181b 
0.28 
(0.036) 
miR-181c 0.096 - 0.56 miR-181c 0.29 (0.043) 
  miR-221 0.25 
  miR-222 0.22 
Table 1. miRNAs significantly deregulated in human glioblastoma tissues 
5. MicroRNAs and invasion 
Invasion of malignant glioma is a highly complex phenomenon involving molecular and 
cellular processes, whose precise interplay is still not fully understood (Tektonidis et al., 
2011). Several studies indicate that one of the possible players in this tumor feature are 
miRNAs (Sana et al., 2011). These observations are highlighted by the recently demonstrated 
relation of some miRNAs with molecules considered key in tumor invasion. Among these 
molecules belongs matrix metalloproteinases (MMPs). MMPs are zinc-containing 
endopeptidases, which degrade the extracellular matrix and basement membrane, and 
process bioactive mediators involved in promoting aspects of tumor growth, including 
gliomas (Badiga et al., 2011; Chetty et al., 2011). The activity of MMPs is regulated at several 
levels, including posttranscriptional regulation through miRNAs (Hadler-Olsen et al., 2011; 
Sana et al., 2011). Sun et al. found that miR-10b induced glioma cell invasion by modulating 
tumor invasion factors MMP-14 and urokinase-type plasminogen activator receptor (uPAR) 
espression via the direct target HOXD10 (Sun et al., 2011). Sasayama et al. came to the same 
conclusion in the study including 43 glioma samples of various grade and 6 glioma cell 
lines. Therefore, the miR-10b/HOXD10/MMP-14/uPAR signaling pathway might 
contribute to the invasion of glioma (Sasayama et al., 2009; Sun et al., 2011). Accordingly, 
glioma cells lost their invasive ability when treated with miR-10b inhibitors, suggesting that 
miR-10b could be used as a new bio-target to cure glioma (Sun et al., 2011). Another group 
established miRNA expression profile (14 positively and 31 negatively correlated miRNAs 
with MMP-9) in 60 GBM samples. Among them, two miRNAs: miR-885-5p and miR-491-5p, 
                                                 
† C/P ratio represents the range of ratio between tumour samples values (C, centre of the tumour) and 
the control samples values (P, peripheral brain area from the same patient) 
‡ P value is presented (Mann-Whitney U-test) 
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were chosen for functional validation for their high positive correlation with MMP-9 
expression. Both miRNAs were demonstrated to reduce the levels of MMP-9 expression and 
inhibit cellular invasion in glioma cells. Furthermore, miR-491-5p suppressed glioma cell 
invasion via targeting MMP-9 directly (Yan et al., 2011). Xia et al. observed that miR-146b 
overexpression by transfection with the precursor miR-146b, or knock-down by LNA-anti-
miR-146b, has no effect on the growth of human glioblastoma cells. However, precursor 
miR-146b transfection significantly reduced the migration and invasion of these cells, while 
LNA-anti-miR-146b transfection generated the opposite result. Furthermore, they 
discovered that MMP16 is one of the downstream targets of miR-146b (Xia et al., 2009). 
Moreover, miR-146-5p supresses translation of EGFR and introduction of miR-146b-5p 
decreases cell invasion, migration, and phosphorylation of protein kinase B (AKT) 
(Katakowski et al., 2010). Another group described regulation of podoplanin membrane 
sialo-glycoprotein (PDPN) through direct targeting of PDPN gene by miR-29b and 125a in 
GBM. Earlier, it was demonstrated that PDPN is over-expressed and related to cellular 
invasion in astrocytic tumors. The similar findings, but in GBM, were published by Cortez et 
al. (Cortez et al., 2010). With GBM invasion are also related miR-124a and miR-34a whose 
targeted over-expression may be novel approach in GBM treatment (Fowler et al., 2011; Li et 
al., 2009a). 
6. MicroRNAs involved in core signaling pathways: Possible therapeutic 
potential 
The involvement of miRNAs in core signaling patways that regulate important cell 
processes of glioblastoma, led to the suggestion that miRNAs could serve as a potential 
therapeutic targets (Novakova et al., 2009; Sana et al., 2011). The most frequently explored 
miRNA is the miR-21, which has been found to act as an oncogene. It is evident that miR-21 
influences multiple important components of oncogenic signaling pathways in 
glioblastoma. MiR-21 was revealed as post-transcriptional regulator involved in NF-κB 
signaling pathway. Aberrant activation of NF-κB signaling pathway has been proved to be 
important for invasiveness and metastatic capacity of tumors through up-regulation of 
matrix metalloproteinases (MMPs) and transcription factors regulating E-cadherin.  Li et al. 
identified LRRFIP1 gene, which was remarkably up-regulated in miR-21-knockdown cells, 
as a candidate target gene of miR-21. Further, they found that LRRFIP1 mRNA carried a 
putative miR-21 binding site. Further analyses confirmed LRRFIP1 as a direct target of miR-
21 (Li et al., 2009b). In connection with this signaling pathway, it was also identified miR-218 
that in vitro dramatically reduced the migratory speed and invasive ability of analysed cells. 
Ectopic expression of miR-218 down-regulated matrix MMP-9 and reduced NF-κB 
transactivity at transcriptional level, whereas inhibition of miR-218 enhanced the expression 
of MMP-9 and transcriptional activity of NF-κB. Authors demonstrated that miR-218 could 
inactivate NF-kB/MMP-9 signaling by directly targeting the 3’-UTR of the IKK-κ which is a 
critical component in NF-κϒϒB regulation (Song et al., 2010). 
PI3K/AKT and EGFR are in term of tumor biology other very important signaling pathways 
that are regulated by miR-21. Mechanistic studies identified mRNA targets of miR-21 among 
important components of the PI3K/AKT and EGFR signaling pathways. Glioblastoma cell 
lines U251 (mutant PTEN) and LN229 (wild-type PTEN) showed a decreased expression of 
EGFR, activated AKT, Cyclin D and Bcl-2 after treatment by miR-21-specific antisense 
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oligonucleotide (Zhou et al., 2010a). Although miR-21 is known to regulate PTEN and 
down-regulation of miR-21 led to increased PTEN expression, the glioblastoma suppressor 
effect of antisense-miR-21 is most likely independent of PTEN status because U251 has 
mutated PTEN (Ren et al., 2010; Zhou et al., 2010a). PTEN down-regulation followed by 
AKT activation was described after transfection of glioblastoma cells with the primary 
transcript of miR-26a-2. Similarly, the miR-26a mimics decreased PTEN protein levels and 
increased AKT phosphorylation (Huse et al., 2009; Kim et al., 2010). Modulation of 
expression levels of AKT signaling cascade components such as Akt1, Cyclin D1, MMP-2, 
MMP-9, and Bcl-2 in glioblastoma cell lines after transfection of miR-451 mimicked was 
described also by Nan. By contrast, miR-451 down-regulation led to increase in p27 levels. 
According to phenotypic experiments, miR-451 inhibited invasive ability, induced cell cycle 
arrest in the G0/G1 phase, delayed the progression of cell cycle, inhibited cell proliferation 
and induced apoptosis in glioblastoma cells in vitro (Nan et al., 2010). Furthermore, miR-451 
affects downstrem members of PI3K/AKT signaling pathway via targeting of CAB39 
(MO25α), which is binding partner of LKB1. LKB1 is upstream kinase of the major energy 
biosensor AMPK. Godlewski published that miR-451 levels are regulated by glucose; under 
conditions of abundant energy miR-451 expression is high, and the suppression of AMPK 
signaling allows cells to maintain elevated proliferation rates via unrestrained mTOR 
activation. Under conditions of glucose withdrawal, miR-451 downregulation is necessary 
for AMPK pathway activation, leading to suppressed proliferation rates, increased cell 
survival and migration. Thus, miR-451 is a regulator of the LKB1/AMPK pathway, and this 
may represent a fundamental mechanism that contributes to cellular adaptation in response 
to altered energy availability (Godlewski et al., 2010a; Godlewski et al., 2010b). MiR-128 is 
another miRNA that significantly reduced glioma cell proliferation in vitro and glioma 
xenograft growth through PI3K/AKT signaling pathway. Godlewski explained this effect by 
binding of mentioned miRNA to the 3’UTR of Bmi-1 mRNA that is significantly up-
regulated in gliomas, wheares miR-128 is down-regulated compared to normal brain. In 
addition, miR-128 expression leads to a decrease in H3K27 methylation and modulation of 
cellular pathways, especially p21CIP1 and Akt, involved in cell cycle arrest and survival 
(Godlewski et al., 2008). Modulation of p21 was described also in context with another 
miRNAs. Gabriely showed that BCL2L11/Bim, TFAP2C/AP-2gamma, CDKN2A/p16, and 
CDKN1A/p21 are direct targets of miR-10b. Inhibition of miR-10b reduced glioma cell 
growth by cell cycle arrest and apoptosis, and, furthermore, survival of glioblastoma 
patients expressing high levels of miR-10 family members is significantly reduced in 
comparison to patients with low miR-10 levels, indicating that miR-10 may contribute to 
glioma growth in vivo (Gabriely et al., 2011). MiR-221 and miR-222 were also revealed as 
potential regulators of many target genes involved in AKT signaling pathway. Up-
regulation of these miRNAs resulted in remarkable increase of p-Akt and significant 
changes in expression of Akt-related genes in glioma cells. Consequently, miR-221 and miR-
222 overexpression increased glioma cell proliferation and invasion in vitro and induced 
glioma growth in a subcutaneous mouse model (Zhang et al., 2010c). EGFR signaling 
network contributes to promotion and progression of a broad spectrum of solid tumors, and 
it is a promising target for anticancer therapy. Stimulation of the EGFR and, subsequently, 
KRAS signaling, lead to activation of numerous signal transduction molecules initiating a 
cascade of downstream effectors that mediate tumour growth, survival, angiogenesis and 
metastasis (Jancik et al., 2010). Kefas published that miR-7 directly inhibited EGFR 
expression via its 3’-UTR and independently suppressed the AKT pathway via targeting 
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upstream regulators, such as IRS-1 and IRS-2. Moreover, transfection with miR-7 
oligonucleotides decreased viability and invasiveness of primary glioblastoma cell lines 
(Kefas et al., 2008). Down-regulation of EGFR mRNA and protein expression in 
glioblastoma cell lines via two predicted sites of miR-7 was confirmed by Webster. This led 
to the induction of cell cycle arrest and apoptosis. Furthermore, the same author also 
described Raf1, another member of the EGFR signaling pathway, as a direct target of miR-7 
in cancer cells (Webster et al., 2009). Katakowski have declared that EGFR is also direct 
target of miR-146b-5p. Its introduction decreased cell invasion, migration, and 
phosphorylation of Akt in glioma cells (Katakowski et al., 2010). Mir-21 is responsible for 
glioma cell invasiveness by disrupting the negative feedback circuit of EGFR components 
Ras/MAPK through post-transcriptional regulation of Spry2. Consistently with these 
results, Spry2 protein levels were significantly decreased in invasive WHO grade II-IV 
human glioma tissues, but not in non-invasive grade I and normal tissues (Kwak et al., 2011) 
(summarized in Fig. 2). 
Other targets of miR-21 are p53, TGF-ȕ, and mitochondrial apoptotic signaling networks. 
Papagiannakopoulos reported that these pathways are de-repressed in response to miR-21 
knockdown. As direct targets of this miRNA were predicted proteins p63, JMY, TP53BP2, 
HNRPK, TOPORS, IGFB3, APAF1, PPIF, TGFBR2/3, DAXX, and HNRNPK. MiR-21 can also 
stabilize p53 protein levels by interfering with MDM2 and/or act as p53 transcriptional 
cofactors (Papagiannakopoulos et al., 2008). Inhibition of miR-21 increased also endogenous 
levels of PDCD4 in human glioma cell lines and activated caspases 9 and 3 (Chen et al., 2008; 
Zhou et al., 2010b). Protein PDCD4 inhibits translation by its interaction with the initiation 
translation factors, and proliferation via activation of p21CIP1 (Kwak et al., 2010). In addition, 
specific inhibition of miR-21 led to reduced MMP activities in vitro and in model of gliomas 
in nude mice. Consequently, down-regulation of miR-21 decreased migratory and invasive 
abilities in glioma cells (Gabriely et al., 2008). Influence on glioma cell invasion by 
modulating MMP was observed also after treatment with miR-10b. This miRNA was 
overexpressed in glioma samples and directly associated with the glioma’s pathological 
grade and malignicy. Sun found that miR-10b affected tumor invasion factors MMP-14 and 
uPAR expression via the direct target HOXD10 (Sun et al., 2011). Finally, it was shown that 
miR-221 and miR-222 directly regulated apoptotic pathway in glioblastoma through direct 
targeting an apoptotic gene PUMA (Zhang et al., 2010b) (summarized in Fig. 2). 
Another study revealed miRNAs as possible regulators of IFN pathways. It was showed 
that STAT1 and STAT2 expression and phosphorylation were up-regulated in cells with 
silenced miR-221 and miR-222. Tyrosine phosphorylation of STAT1 and STAT2 was present 
in the nucleus after repression of the same miRNAs. These data illustrate a mechanism of 
STAT1/2 up-regulation under the transcriptional control of IFN-Ȗ signaling after 
knockdown of miR-221 and miR-222 in glioma cells (Fig. 2) (Zhang et al., 2010a). 
Interestingly, Ohno investigated the possibility that IFN-Ȗ may induce or down-regulate 
cellular miRNAs in human gliomas. They analysed the effect of IFN-Ȗ treatment on miR-21 
expression in glioma cells and intracranial glioma xenografts. Systematic delivery of IFN-Ȗ 
markedly reduced the level of miR-21 in all glioma cells. The results indicate that decrease in 
the levels of miR-21 is the result of transcriptional suppression. In contrast, the addition of 
the STAT3-specific inhibitor increased the level of miR-21 and inhibited IFN-Ȗ–mediated 
suppression of miR-21, suggesting that miR-21 expression is negatively regulated by STAT3 
(Ohno et al., 2009). 
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Fig. 2. MiRNAs involved in core signaling pathways 
Notch signaling is critical in cell fate decisions such as neuronal versus glial fate in the 
developing nervous system. This pathway play also key role in stem-like phenotype 
maintenance and survival of normal stem cells as well as cancer stem cells that are often 
discussed in context with tumor initiation, progression, and metastasis. Therefore, it is not 
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surprising that Notch pathway plays a crucial role in brain tumours, including glioblastoma 
(Kefas et al., 2009; Lathia et al., 2008; Sana et al., 2011). Kefas et al. performed miRNA 
microarray analysis of glioma tumour stem cells transfected with Notch-1 siRNA. In these 
Notch-1 knockdown cells, miR-326 was one of the miRNAs significantly increased. 
However, pre-miR-326 transfection caused substantial decrease in both Notch-1 and Notch-
2 protein. Therefore, it was indicated that miR-326 is suppressed by Notch activity and 
regulates Notch pathway at the same time.  It was observed that miR-326 induces apoptosis 
and decreases glioma cells proliferation, viability and invasiveness of glioblastoma stem 
cell-like lines. Furthermore, miR-326 transfection also reduced glioma cell tumourigenicity 
in vivo (Kefas et al., 2009). Another important target of miRNA-326 is pyruvate kinase type 
M2 (PKM2) that has recently been shown to play a key role in cancer cell metabolism 
(Hitosugi et al., 2009; Kefas et al., 2010). Further, it was studied the role of miR-34a in 
glioblastoma. MiR-34a inhibits Notch-1 and Notch-2 protein expression and 3’-UTR reporter 
activities as well as CDK6 and c-Met protein expression in glioma cells. In this study, Li 
observed for the first time that pre-miR-34a expression is down-regulated in human 
glioblastoma tissues compared to normal human brain (Li et al., 2009a). Other studies 
showed that miR-34a acts as a tumour suppressor in p53-mutant glioma cells, partially 
through regulating SIRT1 (Guessous et al., 2010). Transfection of miR-34a into tested 
glioblastoma cell lines strongly inhibited cell proliferation, cell cycle, cell survival, cell 
invasion and in vivo glioblastoma xenograft growth; however, the treatment did not affect 
human astrocyte cell survival and cell cycle (Luan et al., 2010). 
 
7. Conclusion 
The discovery of miRNA function has markedly spread the view on regulation of gene 
expression. Its remarkable ability to regulate large number of genes, including oncogenes 
and tumor suppressor genes, has catapulted miRNAs into the centre of cancer molecular 
biology over the past few years. It is now evident that dysregulation of miRNAs is an 
important step in the development of many cancers, including gliomas. Some few studies 
based on expression profiling have proven there are significant changes of miRNA 
expression levels in gliomas compared to adult brain tissue; these expression levels 
At a glance 
• MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs able to 
posttranscriptionaly regulate gene expression. 
• MiRNAs are involved in many signalling pathways that have been shown to control 
a wide range of biological processes such as cellular proliferation, differentiation 
and apoptosis. 
• Many miRNAs are deregulated in gliomas and are associated with their biologic 
and clinicopathological features. 
• Expression profiles of selected miRNAs could be used as novel diagnostic and 
prognostic biomarkers as well as possible predictors of therapy response. 
• Targeted regulation of miRNAs in gliomas represents promising therapeutic 
approach leading to the improvement of unsatisfactory survival in glioma patients. 
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identified groups of miRNAs with potential of prognostic stratification and prediction of 
responses to chemoradiotherapy in glioma patients. But much more studies have been 
focused on the improvement our knowledge of role of miRNAs in glioma core signaling 
pathways. The results of these studies suggest a great potential and relevance of miRNAs as 
a novel class of therapeutic targets and possibly powerful intervention tools in glioblastoma. 
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